Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementBlue Cross Blue Shield LA opioid prior auth | Open…
    Ask Trek AI about this page
    Currentblue cross blue shield - louisianaPolicy N/A

    Opioid prescription coverage and prior authorization rules

    Customize your policy alerts

    Sign up for all blue cross blue shield - louisiana policy alerts

    Know when blue cross blue shield - louisiana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for short-acting and long-acting opioid medications for Blue Cross and Blue Shield of Louisiana members, including safety edits and documentation expectations for prescribers.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyOpioid prescription coverage and prior authorization rules
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2022
    Last ReviewJun 1, 2022
    Next Review DateN/A
    Key ActionObtain prior authorization for short-acting opioid fills over a 7-day supply or cumulative >21 days per 60 days and for new users of long-acting opioids unless cancer or end-of-life care.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    42%+reduction in opioid prescriptions per 1,000 members since 2016
    51%+reduction in opioid units per member per month since 2016

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    7 daysmax short-acting fill without PA
    21 days/60dcumulative supply threshold for PA

    Coverage Criteria for Opioid Prescriptions

    inv-01: Short-acting opioids — Prior authorization required when ANY of the following apply

    Prior authorization required for short-acting opioids when ANY of the following apply:

    Short-acting PA triggers: Requested fill longer than a 7-day supply OR cumulative fills longer than a 21-day supply within 60 days>7 days or >21 days per 60 days

    Exceptions for cancer pain or end-of-life care when supported by claims history or provider information

    inv-02: Long-acting opioids — Prior authorization required for new users unless cancer or end-of-life; alternative coverage conditions

    Prior authorization required for long-acting opioids for new users unless cancer or end-of-life care; alternatively, covered when ALL listed criteria are met:

    Long-acting PA general criteria: 1) Patient requires around-the-clock pain control; 2) Prescriber documents an active treatment plan including other pharmacologic and nonpharmacologic agents; 3) Prescriber documents a patient-prescriber agreement addressing prescription management, diversion, doctor/pharmacy shopping and use of other substances; 4) Prescriber has completed an addiction risk assessment

    All four items must be documented if not cancer/end-of-life

    Agent-specific step therapy: If requested drug is one of the specified branded long-acting agents, patient must have tried and failed at least TWO of the listed alternative long-acting opioids (see coding list). For Butrans or branded buprenorphine patch, patient must have tried and failed generic buprenorphine patch AND Belbuca.2 failed alternatives (or both failures for buprenorphine patch)

    Enumerated branded agents and acceptable alternatives are listed in the policy coding sections

    Cancer pain and end-of-life care are exceptions to the prior authorization requirements when supported by claims history or provider documentation. For other indications, prior authorization requirements differ by opioid type.

    For short-acting opioids, prior authorization is required when a requested fill exceeds a 7-day supply or when cumulative fills exceed a 21-day supply within 60 days.

    For long-acting opioids, prior authorization is required for new users unless the request is for cancer pain or end-of-life care. Alternatively, coverage may be authorized when all of the following are documented: 1) patient requires around-the-clock pain control; 2) prescriber documents an active treatment plan including other pharmacologic and nonpharmacologic therapies; 3) a patient–prescriber agreement addressing prescription management/diversion/shopping/other substance use is documented; and 4) an addiction risk assessment has been completed. In addition, certain branded long-acting agents require documented trials and failures of specified alternatives (see coding/step therapy requirements).

    Codes, Supply Thresholds, and Related Limits

    Specified long-acting agents with step requirementsmixed
    Arymo ERlisted branded long-acting opioid requiring step therapy
    Belbucalisted buccal buprenorphine product with step requirements
    Dolophinebrand name methadone product listed
    Duragesic Patchfentanyl patch listed
    Embedalisted long-acting opioid
    Exalgolisted long-acting opioid
    Kadianlisted long-acting opioid
    MS Continlisted long-acting opioid
    Nucynta ERlisted long-acting opioid
    Opana ERlisted long-acting opioid
    1–10 of 15
    1/2
    Acceptable trial alternatives for step therapymixed
    generic buprenorphine patch5 mcg, 7.5 mcg, 10 mcg, 15 mcg, 20 mcg
    generic fentanyl patch12 mcg, 25 mcg, 50 mcg, 75 mcg, 100 mcg
    generic hydromorphone ERalternative long-acting opioid
    generic hydrocodone bitartrate ERalternative long-acting opioid
    Hysingla ERalternative long-acting opioid
    generic methadonealternative long-acting opioid
    generic methadosealternative long-acting opioid
    generic morphine sulfate ERalternative long-acting opioid
    generic morphine sulfate CRalternative long-acting opioid
    inv-06: Short-acting opioid supply threshold — PA required for fills >7 days OR cumulative >21 days within 60 days
    Threshold triggerPrior authorization required for any short-acting opioid fill longer than a 7-day supply
    Cumulative thresholdPrior authorization required for cumulative short-acting opioid supply greater than 21 days within a 60-day period
    ExceptionsCertain exceptions for members with cancer or receiving end-of-life care based on claims history and/or provider information

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Short-acting opioid prior authorization

    Prior authorization required for short-acting opioid fills that exceed quantity limits. Requests for fills greater than a 7-day supply, or a cumulative supply exceeding 21 days within any 60-day period, will require prior authorization. Exceptions apply for members with cancer or those receiving end-of-life care based on claims history and/or provider information.

    • Applies to short-acting opioids (examples: Percocet® and generics, Lortab® and generics, codeine, oxycodone).
    Prior Authorization

    Long-acting opioid new-user prior authorization

    Prior authorization required for new users of long-acting opioids. Certain exceptions apply for members with cancer or receiving end-of-life care based on claims history and/or provider information.

    • Applies to long-acting opioids (examples: Butrans®, fentanyl patch, OxyContin®, MS Contin®, morphine ER, Oxycodone ER).

    Background and Rationale

    Opioid therapies carry significant risks including misuse, dependence, and transition to chronic use. This policy aims to reduce opioid initiation and total opioid exposure by applying supply limits and prior authorization rules that align coverage with clinical expectations and state requirements.

    The policy implements safety edits that limit short-acting opioid supplies — a single fill beyond 7 days or aggregated supplies exceeding 21 days per 60 days trigger prior authorization — and requires more rigorous documentation and step-therapy evidence for new long-acting opioid prescriptions to ensure around-the-clock use is clinically warranted.

    Definitions and Examples

    inv-15: Short-acting opioids (examples provided)
    Examples (nonexhaustive)Percocet and generics; Lortab and generics; codeine; oxycodone
    PA trigger summaryShort-acting opioids require prior authorization when requested fill exceeds 7 days or cumulative supply exceeds 21 days per 60 days
    Related safety editsPolicy also includes acetaminophen, ibuprofen, and aspirin safety edits for combination products (see full policy)
    inv-16: Long-acting opioids (examples provided; new-user PA required)
    Examples (listed agents)Butrans, fentanyl patch (Duragesic), OxyContin, MS Contin, morphine ER, oxycodone ER
    New-user PAPrior authorization required for new users of long-acting opioids (exceptions for cancer or end-of-life care)
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyOpioid prescription coverage and prior authorization rules
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2022
    Last ReviewJun 1, 2022
    Next Review DateN/A
    Key ActionObtain prior authorization for short-acting opioid fills over a 7-day supply or cumulative >21 days per 60 days and for new users of long-acting opioids unless cancer or end-of-life care.
    SourceLink
    On This Page
    Coverage Criteria for Opioid PrescriptionsCodes, Supply Thresholds, and Related LimitsProvider Requirements, Prior Authorization, and DocumentationBackground and RationaleDefinitions and Examples
    Step Therapy

    Step therapy for specified long-acting opioids

    Step therapy applies for specified long-acting opioid agents. For the following requested long-acting agents: Arymo® ER, Belbuca, Dolophine®, Duragesic® Patch, Embeda®, Exalgo®, Kadian®, MS Contin®, Nucynta™ ER, Opana® ER, branded Oxycodone ER, Xartemis® XR, Xtampza™ ER, Zohydro® ER, and Morphabond™ ER, the patient must have tried and failed at least TWO of the listed long-acting alternatives prior to approval.

    • Required trial-and-failure alternatives (try at least two): generic buprenorphine patch (5 mcg, 7.5 mcg, 10 mcg, 15 mcg, 20 mcg); generic fentanyl patch (12 mcg, 25 mcg, 50 mcg, 75 mcg, 100 mcg); generic hydromorphone ER; generic hydrocodone bitartrate ER; Hysingla® ER; generic methadone; generic methadose; generic morphine sulfate ER; generic morphine sulfate CR; OxyContin®.
    Documentation Required

    Step therapy documentation for specific long-acting agents

    Step therapy documentation requirements for specific long-acting agents must be present in the medical record. For requests involving the listed long-acting agents, documentation must demonstrate trials and failures of the specified alternative long-acting opioids (see step therapy list).

    • If the requested drug is Butrans patch or branded Buprenorphine Patch, documentation must show trial and failure of generic buprenorphine patch and Belbuca patch.
    • Ensure medical record contains dates, dosages, duration, and reason for failure or intolerance for each trialed agent.
    Documentation Required

    Required medical record documentation

    Prescribers must document an active treatment plan and a signed patient-prescriber agreement when requesting prior authorization for opioids (short-acting fills exceeding limits or long-acting new-user requests). Prescriber must also have completed an addiction risk assessment.

    • Active treatment plan should include other pharmacologic and nonpharmacologic therapies as appropriate.
    • Patient-prescriber agreement must address prescription management, diversion, doctor/pharmacy shopping, and use of other substances.
    Agent-specific step therapyFor listed branded long-acting agents, patient must have tried and failed at least TWO specified long-acting alternatives (see step list)
    Documentation requirementsPrescriber must document active treatment plan, patient-prescriber agreement, and completed addiction risk assessment